A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells

被引:7
作者
Andersson, E
Henderikx, P
Krambovitis, E
Hoogenboom, HR
Borrebaeck, CAK
机构
[1] Univ Lund, Dept Immunotechnol, S-22007 Lund, Sweden
[2] Univ Hosp, Dept Pathol, CESAME, Maastricht, Netherlands
[3] Maastricht Univ, Maastricht, Netherlands
[4] Inst Mol Biol & Biotechnol, Lab Appl Biochem & Immunol, Heraklion, Greece
关键词
in vitro immunisation; MUC1; human antibodies; phage display; carcinoma;
D O I
10.1007/s002620050528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have recently described an efficient method to study the human humoral immune response in vitro and to generate isotype-switched, antigen-specific human B cells, which has allowed us to produce high-affinity IgG antibodies against different peptides. In an attempt to study the in vitro immune response against self-antigens, such as tumour-associated antigens, this protocol was used to immunise resting human peripheral blood B cells with a peptide epitope from the human-adenocarcinoma-associated antigen, MUC1. After the two-step in vitro immunisation, the secondary immunised cultures were tested for MUC-1-specific antibodies by enzyme-linked immunosorbent assay (ELISA). Phage I;molecular libraries were subsequently constructed, using the variable parts of IE genes derived from cells taken from ELISA-positive wells. The libraries were selected on the MUC1 core peptide. Antigen-specific Fab fragments, specific for the self antigen MUC1, were found in the library of secondary immunised IgG(+) B cells and these antibodies were evaluated by BIAcore analysis. The specific Fab fragments exhibited an unusually rapid dissociation rate constant and the overall response frequency was lower, as compared to other antibodies generated by this protocol, which might be explained by the repetitive nature of the core peptide used for immunisation.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 45 条
[1]   Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].
Agrawal, B ;
Krantz, MJ ;
Reddish, MA ;
Longenecker, BM .
NATURE MEDICINE, 1998, 4 (01) :43-49
[2]  
ATHANASSIOU A, 1988, INT J CANCER, P89
[3]   Making the most of mucin: A novel target for tumor immunotherapy [J].
BarrattBoyes, SM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (03) :142-151
[4]   PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE [J].
BERRUTI, A ;
TAMPELLINI, M ;
TORTA, M ;
BUNIVA, T ;
GORZEGNO, G ;
DOGLIOTTI, L .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (14) :2082-2084
[5]   A SHORT SEQUENCE, WITHIN THE AMINO-ACID TANDEM REPEAT OF A CANCER-ASSOCIATED MUCIN, CONTAINS IMMUNODOMINANT EPITOPES [J].
BURCHELL, J ;
TAYLORPAPADIMITRIOU, J ;
BOSHELL, M ;
GENDLER, S ;
DUHIG, T .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (04) :691-696
[6]  
BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155
[7]  
BURCHELL J, 1987, CANCER RES, V47, P5476
[8]   MIMICKING THE HUMORAL IMMUNE-RESPONSE IN-VITRO RESULTS IN ANTIGEN-SPECIFIC ISOTYPE SWITCHING SUPPORTED BY SPECIFIC AUTOLOGOUS T-HELPER CELLS - GENERATION OF HUMAN HIV-1-NEUTRALIZING IGG MONOCLONAL-ANTIBODIES FROM NAIVE DONORS [J].
CHIN, LT ;
MALMBORG, AC ;
KRISTENSSON, K ;
HINKULA, J ;
WAHREN, B ;
BORREBAECK, CAK .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) :657-663
[9]  
CHIN LT, 1994, IMMUNOLOGY, V81, P428
[10]  
CHOMCZYNSKI P, 1997, CURRENT PROTOCOLS MO, pCH4